These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9763918)

  • 41. Fluorescence in situ hybridization evaluation of minimal residual disease on stem-cell harvests.
    Díez-Martín JL; Buño I; Llamas P; Gosálvez J; López-Fernández C; Polo N; Regidor C
    Cancer Detect Prev; 2000; 24(2):169-72. PubMed ID: 10917138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
    Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
    Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
    [No Abstract]   [Full Text] [Related]  

  • 43. [Leukemia in children].
    Clausen N
    Ugeskr Laeger; 1998 Sep; 160(38):5471. PubMed ID: 9763917
    [No Abstract]   [Full Text] [Related]  

  • 44. [Modern leukemia diagnosis in adults].
    Heilmeier B; Spiekermann K; Bohlander S; Buske C; Feuring-Buske M; Schneider S; Hiddemann W; Braess J
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1222-6. PubMed ID: 19472094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular diagnostics in acute leukemias.
    Bacher U; Schnittger S; Haferlach C; Haferlach T
    Clin Chem Lab Med; 2009; 47(11):1333-41. PubMed ID: 19817644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytogenetics in acute leukemia.
    Mrózek K; Heerema NA; Bloomfield CD
    Blood Rev; 2004 Jun; 18(2):115-36. PubMed ID: 15010150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Importance of minimal residual disease testing during the second year of disease: still no answer?
    Aricò M; Conter V; Valsecchi MG; Masera G
    J Clin Oncol; 2003 Dec; 21(23):4463-4; author reply 4464-5. PubMed ID: 14645441
    [No Abstract]   [Full Text] [Related]  

  • 49. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.
    Krejci O; van der Velden VH; Bader P; Kreyenberg H; Goulden N; Hancock J; Schilham MW; Lankester A; Révész T; Klingebiel T; van Dongen JJ
    Bone Marrow Transplant; 2003 Oct; 32(8):849-51. PubMed ID: 14520434
    [No Abstract]   [Full Text] [Related]  

  • 50. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
    Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia.
    Spanaki A; Linardakis E; Perdikogianni C; Stiakaki E; Morotti A; Cilloni D; Kalmanti M
    Leuk Res; 2007 Apr; 31(4):570-2. PubMed ID: 16876863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia.
    Foroni L; Hoffbrand AV
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):71-90. PubMed ID: 11987917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current status of diagnosis and prognosis of infant acute leukemia in China.
    Huang LB; Guan XQ; Zhang YC; Zhang XL; Ke ZY; Luo XQ
    Pediatr Blood Cancer; 2009 Dec; 53(6):973-7. PubMed ID: 19588516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The contribution of monoclonal antibodies to the diagnosis and prognosis of acute leukemias (apropos of 100 cases)].
    Bernier M; Massy M; Delforge A; Lagneaux L; Bron D; Debusscher L; Stryckmans P
    Rev Med Brux; 1988 Dec; 9(10):448-54. PubMed ID: 2852390
    [No Abstract]   [Full Text] [Related]  

  • 56. Acute leukemia: detection and therapeutics.
    McGuire TR
    Am Pharm; 1990 Feb; NS30(2):29, 32-4. PubMed ID: 2407080
    [No Abstract]   [Full Text] [Related]  

  • 57. [Diagnostics of acute leukemias: interaction of phenotypic and genetic methods].
    Bacher U; Haferlach C; Schnittger S; Kern W; Ott MM; Haferlach T
    Pathologe; 2012 Nov; 33(6):528-38. PubMed ID: 23085696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of minimal residual disease in acute myeloblastic leukemia.
    Freireich EJ
    Prog Clin Biol Res; 1994; 389():579-85. PubMed ID: 7700923
    [No Abstract]   [Full Text] [Related]  

  • 59. [Current aspects of the laboratory diagnosis of acute leukemia in children].
    van Wering ER
    Tijdschr Kindergeneeskd; 1988 Apr; 56(2):50-4. PubMed ID: 3287683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Current diagnosis of acute leukemia (lecture)].
    Frenkel' MA
    Klin Lab Diagn; 1999 Jan; (1):25-32. PubMed ID: 10097492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.